Evidence map›Paper›PMID 37960029›Full record

ArticlePlants (Basel, Switzerland)2023

Date Palm Extract (

Heba S Elsewedy, Tamer M Shehata, Nashi K Alqahtani, Hany Ezzat Khalil, Wafaa E Soliman

Abstract read
In one paragraph

Article in Plants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Bridging bioactive metabolites ofFrontiers in pharmacology · 2026
    Review
  2. Relevance of topical application of minoxidil laden nano-lipid for hair growth enhancement.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  3. Article
  4. Investigating topical delivery of erythromycin laden into lipid nanocarrier for enhancing the anti-bacterial activity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heba S ElsewedyDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Alhofuf 31982, Al-Ahsa, Saudi Arabia.ORCID 0000-0002-3221-9168
Tamer M ShehataDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Alhofuf 31982, Al-Ahsa, Saudi Arabia.ORCID 0000-0002-8051-1614
Nashi K AlqahtaniDepartment of Food Science and Technology, College of Agriculture, King Faisal University, Alhofuf 31982, Al-Ahsa, Saudi Arabia.ORCID 0000-0002-7190-4256
Hany Ezzat KhalilDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Alhofuf 31982, Al-Ahsa, Saudi Arabia.ORCID 0000-0001-7892-3380
Wafaa E SolimanDepartment of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Alhofuf 36362, Al-Ahsa, Saudi Arabia.ORCID 0000-0001-6549-0926

Funding

Date palm Research Center of Excellence, King Faisal University, grant number DPRC-03-2022 grant number DPRC-03-2022
6 · The paper itself

Abstract

It is worthwhile to note that using natural products today has shown to be an effective strategy for attaining the therapeutic goal with the highest impact and the fewest drawbacks. In Saudi Arabia, date palm (Phoenix dactylifera) is considered the principal fruit owing to its abundance and incredible nutritional benefits in fighting various diseases. The main objective of the study is to exploit the natural products as well as the nanotechnology approach to obtain great benefits in managing disorders. The present investigation focused on using the powder form of date palm extract (DPE) of Khalas cultivar and incorporates it into a nanolipid formulation such as a nanostructured lipid carrier (NLC) prepared with palm oil. Using the quality by design (QbD) methodology, the most optimized formula was chosen based on the number of assigned parameters. For more appropriate topical application, the optimized DP-NLC was combined with a pre-formulated hydrogel base forming the DP-NLC-hydrogel. The developed DP-NLC-hydrogel was evaluated for various physical properties including pH, viscosity, spreadability, and extrudability. Additionally, the in vitro release of the formulation as well as its stability upon storage under two different conditions of room temperature and refrigerator were investigated. Eventually, different bacterial strains were utilized to test the antibacterial efficacy of the developed formulation. The optimized DP-NLC showed proper particle size (266.9 nm) and in vitro release 77.9%. The prepared DP-NLC-hydrogel showed acceptable physical properties for topical formulation, mainly, pH 6.05, viscosity 9410 cP, spreadability 57.6 mm, extrudability 84.5 (g/cm

Indexed as

antibacterialdate palm extractnanolipid carriernatural productsoptimizationpalm oiltopical drug delivery

Identifiers

PMID37960029
PMCPMC10648499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.